美国高盛两篇研究报告

是 否 +2 论坛币

k人 参与回答

经管之家送您一份

应届毕业生专属福利!

求职就业群

赵安豆老师微信：zhaoandou666

经管之家联合CDA

送您一个全额奖学金名额~ !

立即领取

感谢您参与论坛问题回答

经管之家送您两个论坛币！

+2 论坛币

News
On November 29, 2010, NDRC issued an announcement to lower the
retail price cap by an average of 19% among 17 therapeutic drug
categories, primarily antibiotics and cardiovascular medicines. The
announcement stipulates (1) lowering the retail prices of selected
independently priced medicines, and (2) removal of independent pricing of
certain products. NDRC expects to save c.Rmb2 bn per year for the public
by implementing these measures. Roche’s Rocephin (Ceftriaxone Sodium
0.25g/0.5g/1g, Bristol-Myers-Squibb’s Capoten (Captopril), MSD (Merck
Sharpe & Dohme)’s Vasatec (Enapril) 10mg*10/5mg*10, Daiichi
Sankyo’s Levaquin (Levofloxacin) 100mg*10/500mg*4/300mg (100ml,
injection)/500mg (100ml injection), Novartis’ Cataflam (Diclofenac
Potassium) 25mg*10 (pills)/25mg*10/25mg*30 (enteric coated tablets),
Pfizer’s Zithromax (Azithromycin) 250mg*4/250mg*4 and the United
Lab’s Amoxicillin 250mg*24/500mg*12/500mg*24, are a few among the
list.

扫码加我 拉你入群

请注明：姓名-公司-职位

以便审核进群资格，未注明则拒绝

分享0 收藏1 回帖

关键词：研究报告 announcement Implementing Independent categories 美国 研究报告 高盛

谢谢分享！！！！！

谢谢分享！！！！！

谢谢分享！！！！！

谢谢分享！！！！！

谢谢分享！！！！！

谢谢分享！！！！！

谢谢分享！！！！！

谢谢分享！！！！！

谢谢分享！！！！！